CAMKK2 and prostate carcinoma: Moreover, if CAMKK2’s hepatic functions are proven to be a major driver of prostate cancer progression, this could present new opportunities from a drug development/pharmacokinetic standpoint, given that many drugs often accumulate in the liver [58].